Astrazeneca Plc (AZN) To Go Ex-Dividend on August 7th

Astrazeneca Plc (NYSE:AZN) declared a dividend on Tuesday, February 10th. Shareholders of record on Friday, August 7th will be paid a dividend of 0.795 per share on Tuesday, September 8th. This represents a yield of 94.0%. The ex-dividend date is Friday, August 7th.

Astrazeneca has increased its dividend by an average of 0.0%per year over the last three years. Astrazeneca has a dividend payout ratio of 85.3% meaning its dividend is currently covered by earnings, but may not be in the future if the company’s earnings fall. Research analysts expect Astrazeneca to earn $11.39 per share next year, which means the company should continue to be able to cover its $4.34 annual dividend with an expected future payout ratio of 38.1%.

Astrazeneca Stock Performance

NYSE:AZN opened at $155.79 on Wednesday. The company has a market capitalization of $241.61 billion, a P/E ratio of 23.29, a P/E/G ratio of 1.36 and a beta of 0.26. The business has a fifty day simple moving average of $177.81 and a two-hundred day simple moving average of $187.53. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. Astrazeneca has a 1 year low of $145.79 and a 1 year high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.13. The firm had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.17 EPS. On average, analysts expect that Astrazeneca will post 10.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AZN. Triumph Capital Management purchased a new stake in shares of Astrazeneca in the third quarter worth about $25,000. MV Capital Management Inc. bought a new position in shares of Astrazeneca in the fourth quarter valued at approximately $26,000. Mascoma Wealth Management LLC purchased a new position in Astrazeneca during the first quarter valued at approximately $26,000. Roxbury Financial LLC purchased a new position in Astrazeneca during the second quarter valued at approximately $29,000. Finally, Eagle Bay Advisors LLC bought a new stake in Astrazeneca during the 4th quarter worth approximately $30,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.